Vyne Therapeutics Inc's Customers Performance

Name: Vyne Therapeutics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

VYNE

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


VYNE's Source of Revenues		During the corresponding time, Vyne Therapeutics Inc recorded a revenue increase by 40.58 % year on year, sequentially revenue grew by 12.79 %. While revenue at the Vyne Therapeutics Inc 's corporate clients • List of VYNE Customers

for the same period Vyne Therapeutics Inc recorded revenue increase by 40.58 % year on year, sequentially revenue grew by 12.79 %.

• List of VYNE Customers

Vyne Therapeutics Inc's Business Units


Royalty revenues Reportable Segment		188.66 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Vyne Therapeutics Inc's Comment on Sales, Marketing and Customers

The company holds intellectual property rights and maintains patent portfolios related to its BET inhibitor and repibresib programs. These portfolios include patent applications filed in various jurisdictions and involve licensing arrangements.

News about Vyne Therapeutics Inc Contracts

VYNE Therapeutics Pioneers BD2-Selective BET Inhibitor VYN202 in Phase 1a Clinical Trials A Step Forward in Targeted ...

Dosing Commences in Phase 1a Trial of BD2-Selective BET Inhibitor VYN202 by VYNE Therapeutics The advent of epigenetic modulation presents a burgeoning frontier in pharmaceutical sciences, offering promising avenues for targeted therapeutics. Among these, Bromodomain and Extraterminal domain (BET) inhibitors stand as pivotal agents in disrupting the proliferation of oncogenic processes. VYNE Therapeutics, a leader in innovative pharmaceutical research, has recently commenced dosing in a Phase 1a clinical trial of its novel BD2-selective BET inhibitor, VYN202. This study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VYN202 in healthy subjects, marking a significant mile...

Vyne Therapeutics Inc’s Comment on Sales, Marketing and Customers

VYNE's Stock Performance relative to it's Customers

VYNE's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Vyne Therapeutics Inc	22.56	0.54	-17.91	10
SUBTOTAL	0.00	0.00	0.00	-

Sources: Vyne Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Vyne Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Vyne Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.